Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
ChEMBL v34 compound record for TIRZEPATIDE (CHEMBL4297839): max_phase 4 (approved), first_approval 2022, parenteral, GIP receptor agonist, first-in-class, black-box warning flag
Products are provided in lyophilised (powder) form and require proper reconstitution before use in research settings
When applied in animal models, 5-Amino-1MQ has demonstrated the capacity to reduce tumor cell proliferation and alter the tumor microenvironment in favor of therapeutic intervention
Stopping treatment leads to gradual return to baseline hair density within ~ 8 weeks
Un test cutan intradermique doit tre effectu s'il y a un risque d'hypersensibilit
In vitro assays using BaF-BO3 cells transfected with the hGH receptor confirmed that AOD9604 does not compete for the hGH receptor and does not induce cell proliferation unlike intact hGH establishing that it operates via a novel mechanism distinct from traditional hGH-stimulated pathways
US$ 29.02
US$ 22.87
US$ 23.16
US$ 24.52
US$ 24.02
US$ 27.56
US$ 29.87
US$ 29.15
US$ 23.58
US$ 28.88
US$ 27.52
